Classifications

• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
  • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
  • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
  • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Nanotechnology (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Polymers & Plastics (AREA)
• General Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Crystallography & Structural Chemistry (AREA)
• Medical Informatics (AREA)
• Materials Engineering (AREA)
• Biophysics (AREA)
• Biotechnology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Medicinal Preparation (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Saccharide Compounds (AREA)
• Detergent Compositions (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10985114

Family Applications (1)

Country Status (32)

Families Citing this family (14)

Family Cites Families (7)

• 1994
  • 1994-04-26 HU HU9401183A patent/HU218280B/hu not_active IP Right Cessation
• 1995
  • 1995-04-25 MD MD95-0440A patent/MD1419G2/ro unknown
  • 1995-04-25 DK DK95918104T patent/DK0705255T3/da active
  • 1995-04-25 IL IL11349195A patent/IL113491A/en not_active IP Right Cessation
  • 1995-04-25 BR BR9506155A patent/BR9506155A/pt not_active Application Discontinuation
  • 1995-04-25 EP EP95918104A patent/EP0705255B1/en not_active Expired - Lifetime
  • 1995-04-25 JP JP52720795A patent/JP3434828B2/ja not_active Expired - Lifetime
  • 1995-04-25 PL PL95312183A patent/PL312183A1/xx unknown
  • 1995-04-25 PT PT95918104T patent/PT705255E/pt unknown
  • 1995-04-25 AU AU24159/95A patent/AU694219B2/en not_active Expired
  • 1995-04-25 WO PCT/HU1995/000011 patent/WO1995029172A1/en not_active Ceased
  • 1995-04-25 YU YU25995A patent/YU25995A/sh unknown
  • 1995-04-25 DE DE69519463T patent/DE69519463T2/de not_active Expired - Lifetime
  • 1995-04-25 US US08/571,853 patent/US5698535A/en not_active Expired - Fee Related
  • 1995-04-25 RU RU96100760A patent/RU2136698C1/ru active
  • 1995-04-25 CN CN95190353A patent/CN1060164C/zh not_active Expired - Fee Related
  • 1995-04-25 NZ NZ285149A patent/NZ285149A/en unknown
  • 1995-04-25 ES ES95918104T patent/ES2153897T3/es not_active Expired - Lifetime
  • 1995-04-25 RO RO95-02248A patent/RO114449B1/ro unknown
  • 1995-04-25 CA CA002163539A patent/CA2163539C/en not_active Expired - Lifetime
  • 1995-04-25 SI SI9530435T patent/SI0705255T1/xx unknown
  • 1995-04-25 SK SK1551-95A patent/SK155195A3/sk unknown
  • 1995-04-25 KR KR1019950705912A patent/KR960703404A/ko not_active Ceased
  • 1995-04-25 AT AT95918104T patent/ATE197708T1/de active
  • 1995-04-25 CZ CZ953163A patent/CZ316395A3/cs unknown
  • 1995-04-25 HR HRP9401183A patent/HRP950249A2/hr not_active Application Discontinuation
  • 1995-12-20 FI FI956156A patent/FI956156A7/fi not_active Application Discontinuation
  • 1995-12-22 LV LVP-95-383A patent/LV11543B/en unknown
  • 1995-12-22 NO NO19955283A patent/NO311030B1/no not_active IP Right Cessation
  • 1995-12-22 LT LT95-133A patent/LT4167B/lt not_active IP Right Cessation
• 1996
  • 1996-01-26 BG BG100313A patent/BG61974B1/bg unknown
• 2001
  • 2001-02-02 GR GR20010400181T patent/GR3035356T3/el unknown

Also Published As

Similar Documents

Legal Events